Elements of cancer immunity and the cancer–immune set point
The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
Abstract
Immunotherapy is proving to be an effective therapeutic approach in a variety of cancers. But despite the clinical success of antibodies against the immune regulators CTLA4 and PD-L1/PD-1, only a subset of people exhibit durable responses, suggesting that a broader view of cancer immunity is required. Immunity is influenced by a complex set of tumour, host and environmental factors that govern the strength and timing of the anticancer response. Clinical studies are beginning to define these factors as immune profiles that can predict responses to immunotherapy. In the context of the cancer-immunity cycle, such factors combine to represent the inherent immunological status - or 'cancer-immune set point' - of an individual.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This model effectively identifies two main clusters resembling the Immune-Inflamed and Immune-Desert phenotypes42–44”
From Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images (2024) · cites this paper as [43]
In the citing paper
“Tumor-infiltrating lymphocytes (TILs) have been proven to be associated with immunotherapy response 245, OS, and PFS 246.”
From Artificial intelligence in pancreatic cancer (2022) · cites this paper as [245]
In the citing paper
“The microbiota influences the cancer-immune set point, which is the threshold beyond which an immune response can be elicited in a given individual.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [11]
In the citing paper
“Recently, it has been demonstrated that the efficacy of the treatment with immune checkpoint inhibitors can be influenced by the composition of the host gut microbiota (176).”
From Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention (2019) · cites this paper as [176]
In the citing paper
“a variety of clinically relevant anticancer interventions including conventional chemotherapeutics (Galluzzi et al., 2020a), radiation therapy (RT) (Rodriguez-Ruiz et al., 2020), and targeted anticancer agents (see main text) have been shown to elicit bona fide ICD and hence jumpstart the cancer-immunity cycle (Chen and Mellman, 2017) in preclinical tumor models.”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Chen and Mellman, 2017
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Self-citation
Cited by
Items 301–400 of 1,026
Yagi, T., Baba, Y., Ishimoto, T., Iwatsuki, M., Miyamoto, Y., Yoshida, N., Watanabe, M., & Baba, H. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000002616 · Cited by 182
“Thus, PD-1 and PD-L1 have attracted much attention for their roles in tumor immunology and as immune-based therapeutic targets.(8,10,11) Recently, many clinical trials for PD-1/PD-L1 signal-blockade agents have demonstrated dramatic antitumor efficacy in patients with numerous types of malignancies, including esophage…”
BackgroundBarroso-Sousa, R., Keenan, T. E., Pernas, S., Exman, P., Jain, E., Garrido-Castro, A. C., Hughes, M., Bychkovsky, B., Umeton, R., Files, J. L., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3507 · Cited by 182
“Clin Cancer Res; 26(11) June 1, 2020 CLINICAL CANCER RESEARCH 2566”
BackgroundInfluentialLandscape of Immune Microenvironment Under Immune Cell Infiltration Pattern in Breast Cancer
Xu, Q., Chen, S., Hu, Y., & Huang, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.711433 · Cited by 180
PD-1 pathway regulates ILC2 metabolism and PD-1 agonist treatment ameliorates airway hyperreactivity
Helou, D. G., Shafiei-Jahani, P., Lo, R., Howard, E., Hurrell, B. P., Galle-Treger, L., Painter, J. D., Lewis, G., Soroosh, P., Sharpe, A. H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17813-1 · Cited by 178
Hu, M., Zhang, J., Kong, L., Yu, Y., Hu, Q., Yang, T., Wang, Y., Tu, K., Qiao, Q., Qin, X., et al. (2021) · ACS Nano · doi:10.1021/acsnano.0c09681 · Cited by 179
Metastatic disease in head & neck oncology
Pisani, P., Airoldi, M., Allais, A., Aluffi Valletti, P., Battista, M., Benazzo, M., Briatore, R., Cacciola, S., Cocuzza, S., Colombo, A., et al. (2020) · Acta Otorhinolaryngologica Italica · doi:10.14639/0392-100x-suppl.1-40-2020 · Cited by 177
Germline genetic contribution to the immune landscape of cancer
Sayaman, R. W., Saad, M., Thorsson, V., Hu, D., Hendrickx, W., Roelands, J., Porta-Pardo, E., Mokrab, Y., Farshidfar, F., Kirchhoff, T., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.01.011 · Cited by 179
FAK in Cancer: From Mechanisms to Therapeutic Strategies
Chuang, H.-H., Zhen, Y.-Y., Tsai, Y.-C., Chuang, C.-H., Hsiao, M., Huang, M.-S., & Yang, C.-J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031726 · Cited by 174
“In tumor progression, heterogeneous immune cells play distinct roles in promoting either clearance or immune evasion [188].”
BackgroundApoptosis in Cancer Biology and Therapy
Moyer, A., Tanaka, K., & Cheng, E. H. (2025) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-051222-115023 · Cited by 173
Patient-derived tumor organoids for prediction of cancer treatment response
Nagle, P. W., Plukker, J. T. M., Muijs, C. T., van Luijk, P., & Coppes, R. P. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.06.005 · Cited by 175
“Furthermore, treatment response is also influenced by the tumor microenvironment, such as localized regions of hypoxia [94], and by the surrounding immune system [95].”
BackgroundDual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatment
Gulley, J. L., Schlom, J., Barcellos‐Hoff, M. H., Wang, X., Seoane, J., Audhuy, F., Lan, Y., Dussault, I., & Moustakas, A. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13146 · Cited by 175
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01363-8 · Cited by 175
Multiscale Agent-Based and Hybrid Modeling of the Tumor Immune Microenvironment
Norton, K.-A., Gong, C., Jamalian, S., & Popel, A. S. (2019) · Processes · doi:10.3390/pr7010037 · Cited by 175
Molecular Mechanisms and Emerging Therapeutic Targets of Triple-Negative Breast Cancer Metastasis
Neophytou, C., Boutsikos, P., & Papageorgis, P. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00031 · Cited by 173
“Importantly, recent studies have shown that tumor cells are able to evade immune responses by activating negative regulatory pathways, also known as immune checkpoints, that block T-cell activation through cytotoxic T-lymphocyte protein 4 (CTLA4) or via binding of the programmed cell death protein 1 (PD1) receptor exp…”
BackgroundDiverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms
Bezzi, M., Seitzer, N., Ishikawa, T., Reschke, M., Chen, M., Wang, G., Mitchell, C., Ng, C., Katon, J., Lunardi, A., et al. (2018) · Nature Medicine · doi:10.1038/nm.4463 · Cited by 172
A single-cell tumor immune atlas for precision oncology
Nieto, P., Elosua-Bayes, M., Trincado, J. L., Marchese, D., Massoni-Badosa, R., Salvany, M., Henriques, A., Nieto, J., Aguilar-Fernández, S., Mereu, E., et al. (2021) · Genome Research · doi:10.1101/gr.273300.120 · Cited by 169
“Spatial localization of immune cells in tumor sections Widespread evidence indicates that the spatial distribution of immune cells is important for ICI response (Chen and Mellman 2017).”
BackgroundInfluentialYang, W., Feng, Y., Zhou, J., Cheung, O. K.-W., Cao, J., Wang, J., Tang, W., Tu, Y., Xu, L., Wu, F., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz6804 · Cited by 172
“In this immune-excluded phenotype, T cell migration through the tumor stroma is recognized as the rate-limiting step for ICB therapy, as CD8+ T cells show evidence of activation and proliferation, but not infiltration, upon treatment (1).”
BackgroundInfluentialT lymphocyte subsets in cancer immunity: Friends or foes
Chraa, D., Naim, A., Olive, D., & Badou, A. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.mr0318-097r · Cited by 172
Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
Middelburg, J., Kemper, K., Engelberts, P., Labrijn, A. F., Schuurman, J., & van Hall, T. (2021) · Cancers · doi:10.3390/cancers13020287 · Cited by 170
“spond to immune checkpoint therapy [77], (2) “immune desert” tumors, which have a”
BackgroundBeyond matrix stiffness: targeting force-induced cancer drug resistance
Kalli, M., Poskus, M. D., Stylianopoulos, T., & Zervantonakis, I. K. (2023) · Trends in Cancer · doi:10.1016/j.trecan.2023.07.006 · Cited by 167
“The dense ECM can also act as a physical barrier to immune cell infiltration, contributing to the formation of an immune-excluded phenotype [10,11].”
BackgroundNanomedicine‐Based Immunotherapy for the Treatment of Cancer Metastasis
Zhang, P., Zhai, Y., Cai, Y., Zhao, Y., & Li, Y. (2019) · Advanced Materials · doi:10.1002/adma.201904156 · Cited by 171
Discovering dominant tumor immune archetypes in a pan-cancer census
Combes, A. J., Samad, B., Tsui, J., Chew, N. W., Yan, P., Reeder, G. C., Kushnoor, D., Shen, A., Davidson, B., Barczak, A. J., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.004 · Cited by 169
Zheng, S., Wang, W., Shen, L., Yao, Y., Xia, W., & Ni, C. (2024) · Experimental Hematology & Oncology · doi:10.1186/s40164-024-00543-1 · Cited by 163
“Immune-desert (also referred to as “cold” or “ignored”) tumors, as the name suggests, indicate a paucity or absence of T cells either in the tumor core or periphery, though myeloid cells may be present instead [21, 25, 28, 29].”
BackgroundInfluentialEmerging Principles in Myelopoiesis at Homeostasis and during Infection and Inflammation
Schultze, J. L., Mass, E., & Schlitzer, A. (2019) · Immunity · doi:10.1016/j.immuni.2019.01.019 · Cited by 167
Chafe, S. C., McDonald, P. C., Saberi, S., Nemirovsky, O., Venkateswaran, G., Burugu, S., Gao, D., Delaidelli, A., Kyle, A. H., Baker, J. H. E., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0657 · Cited by 165
Genomic instability, inflammatory signaling and response to cancer immunotherapy
Chen, M., Linstra, R., & van Vugt, M. A. T. M. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188661 · Cited by 166
Macrophage targeting: opening new possibilities for cancer immunotherapy
Cassetta, L., & Kitamura, T. (2018) · Immunology · doi:10.1111/imm.12976 · Cited by 166
“, peritumoral stroma) and fail to reach and eliminate tumour cells.(36) Indeed, a recent study demonstrated that urothelial cancers in patients who did not respond to anti-PDL1 agent showed a low tumour mutation rate and a preferential accumulation of CD8 T cells in the fibroblast rich peritumoural stroma rather than…”
BackgroundIntegrative proteogenomic characterization of hepatocellular carcinoma across etiologies and stages
Ng, C. K. Y., Dazert, E., Boldanova, T., Coto-Llerena, M., Nuciforo, S., Ercan, C., Suslov, A., Meier, M.-A., Bock, T., Schmidt, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29960-8 · Cited by 165
Chemically programmed STING-activating nano-liposomal vesicles improve anticancer immunity
Chen, X., Meng, F., Xu, Y., Li, T., Chen, X., & Wang, H. (2023) · Nature Communications · doi:10.1038/s41467-023-40312-y · Cited by 160
“However, only a small subset of patients bene fi t from this treatment 2 .”
Melaiu, O., Chierici, M., Lucarini, V., Jurman, G., Conti, L. A., De Vito, R., Boldrini, R., Cifaldi, L., Castellano, A., Furlanello, C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19781-y · Cited by 163
Harnessing non-destructive 3D pathology
Liu, J. T. C., Glaser, A. K., Bera, K., True, L. D., Reder, N. P., Eliceiri, K. W., & Madabhushi, A. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00681-x · Cited by 163
Xu, Y., Su, G.-H., Ma, D., Xiao, Y., Shao, Z.-M., & Jiang, Y.-Z. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00729-7 · Cited by 163
“226 Nonetheless, a considerable proportion of TILs are only a bystander without cytolytic effects on tumor cells.”
BackgroundYi, M., Niu, M., Zhang, J., Li, S., Zhu, S., Yan, Y., Li, N., Zhou, P., Chu, Q., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01155-6 · Cited by 163
Xie, F., Zhou, X., Su, P., Li, H., Tu, Y., Du, J., Pan, C., Wei, X., Zheng, M., Jin, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31250-2 · Cited by 163
Cao, Y., Trillo-Tinoco, J., Sierra, R. A., Anadon, C., Dai, W., Mohamed, E., Cen, L., Costich, T. L., Magliocco, A., Marchion, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09263-1 · Cited by 161
State-of-the-art advances of copper-based nanostructures in the enhancement of chemodynamic therapy
Hao, Y.-N., Zhang, W.-X., Gao, Y.-R., Wei, Y.-N., Shu, Y., & Wang, J.-H. (2021) · Journal of Materials Chemistry B · doi:10.1039/d0tb02360d · Cited by 161
Anti-TIGIT therapies for solid tumors: a systematic review
Rousseau, A., Parisi, C., & Barlesi, F. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101184 · Cited by 158
“Immune checkpoint molecules are key modulators of the anti-tumor T-cell response.(3) In physiologic conditions, inhibitory immune checkpoint receptors play a vital role in maintaining immune self-tolerance and preventing T cells”
BackgroundHaas, Q., Boligan, K. F., Jandus, C., Schneider, C., Simillion, C., Stanczak, M. A., Haubitz, M., Jafari, S. M. S., Zippelius, A., Baerlocher, G. M., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0505 · Cited by 173
Fibroblasts Fuel Immune Escape in the Tumor Microenvironment
De Jaeghere, E. A., Denys, H. G., & De Wever, O. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.09.009 · Cited by 160
Shae, D., Baljon, J. J., Wehbe, M., Christov, P. P., Becker, K. W., Kumar, A., Suryadevara, N., Carson, C. S., Palmer, C. R., Knight, F. C., et al. (2020) · ACS Nano · doi:10.1021/acsnano.0c02765 · Cited by 160
Modulating inflammation for cancer therapy
Ritter, B., & Greten, F. R. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20181739 · Cited by 159
Sui, S., An, X., Xu, C., Li, Z., Hua, Y., Huang, G., Sui, S., Long, Q., Sui, Y., Xiong, Y., et al. (2020) · Theranostics · doi:10.7150/thno.49451 · Cited by 158
“Tumor progression is a complex process that requires interaction between cancer cells, the microenvironment, and the immune system, influencing both tumor initiation and progression [1].”
BackgroundQu, S., Fetsch, P. A., Thomas, A., Pommier, Y. G., Schrump, D. S., Miettinen, M., & Chen, H. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.08.763 · Cited by 173
Immune suppression and reversal of the suppressive tumor microenvironment
Shimizu, K., Iyoda, T., Okada, M., Yamasaki, S., & Fujii, S.-I. (2018) · International Immunology · doi:10.1093/intimm/dxy042 · Cited by 157
Titin mutation associated with responsiveness to checkpoint blockades in solid tumors
Jia, Q., Wang, J., He, N., He, J., & Zhu, B. (2019) · JCI Insight · doi:10.1172/jci.insight.127901 · Cited by 158
Advances in Multiple Stimuli-Responsive Drug-Delivery Systems for Cancer Therapy
Jia, R., Teng, L., Gao, L., Su, T., Fu, L., Qiu, Z., & Bi, Y. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s293427 · Cited by 184
The role of dendritic cells in cancer
(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.07.006 · Cited by 157
Li, F., Zhang, X., Ho, W., Tang, M., Li, Z., Bu, L., & Xu, X. (2023) · Nature Communications · doi:10.1038/s41467-023-39938-9 · Cited by 178
PD-L1 expression testing in non-small cell lung cancer
Teixidó, C., Vilariño, N., Reyes, R., & Reguart, N. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918763493 · Cited by 156
A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9)
Lv, Y., Ma, X., Ma, Y., Du, Y., & Feng, J. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.05.020 · Cited by 171
Targeting immune checkpoints in breast cancer: an update of early results
Solinas, C., Gombos, A., Latifyan, S., Piccart, M. J., Kok, M., & Buisseret, L. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000255 · Cited by 166
“The genomic landscape likely has a role in determining the putative immunogenicity of the tumour(122); TIL, PD-L1 expression and immune gene signatures could detect tumours with an inflamed phenotype, which have higher chances of response to ICB.(111) 123 Noteworthy, spontaneous antitumour immune infiltration was show…”
BackgroundInfluentialTrial watch: Peptide-based vaccines in anticancer therapy
Bezu, L., Kepp, O., Cerrato, G., Pol, J., Fucikova, J., Spisek, R., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1511506 · Cited by 155
“malignant and malignant cells naturally as well as in response to some treatment regimens.(9,20,21,260) Such knowledge has”
BackgroundTian, P., He, B., Mu, W., Liu, K., Liu, L., Zeng, H., Liu, Y., Jiang, L., Zhou, P., Huang, Z., et al. (2021) · Theranostics · doi:10.7150/thno.48027 · Cited by 155
“Given the overall response rates to ICI treatment, ranging from 14% to 20% in unselected patients [3,4], it is essential to identify predictive biomarkers for the selection of patients who are more likely to respond to immunotherapy.”
BackgroundBasurto‐Lozada, P., Molina‐Aguilar, C., Castaneda‐Garcia, C., Vázquez‐Cruz, M. E., Garcia‐Salinas, O. I., Álvarez‐Cano, A., Martínez‐Said, H., Roldán‐Marín, R., Adams, D. J., Possik, P. A., et al. (2021) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12885 · Cited by 154
“Their cellular and molecular properties are determinants of melanoma progression and therapeutic response (Chen & Mellman, 2017).”
BackgroundSize matters: Dissecting key parameters for panel‐based tumor mutational burden analysis
Buchhalter, I., Rempel, E., Endris, V., Allgäuer, M., Neumann, O., Volckmar, A., Kirchner, M., Leichsenring, J., Lier, A., von Winterfeld, M., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.31878 · Cited by 154
Doi, T., Muro, K., Ishii, H., Kato, T., Tsushima, T., Takenoyama, M., Oizumi, S., Gemmoto, K., Suna, H., Enokitani, K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1090 · Cited by 162
“In patients with pancreatic adenocarcinoma, we observed one confirmed PR and two unconfirmed PRs, which is notable because pancreatic cancer restricts the access of immune cells to the tumor parenchyma (24) and is poorly responsive to anti– PD-1/PD-L1 antibodies (25, 26).”
BackgroundPetitprez, F., Lévy, S., Sun, C., Meylan, M., Linhard, C., Becht, É., Elarouci, N., Tavel, D., Roumenina, L. T., Ayadi, M., et al. (2020) · Genome Medicine · doi:10.1186/s13073-020-00783-w · Cited by 190
“Due to the rapidly increasing, almost impossible to handle, number of agents tested in immunotherapy clinical trials [30, 31], it is of paramount importance to test them in pre-clinical models with a method that robustly and sensitively quantifies the TME composition.”
BackgroundExpansion of T memory stem cells with superior anti-tumor immunity by Urolithin A-induced mitophagy
Denk, D., Petrocelli, V., Conche, C., Drachsler, M., Ziegler, P. K., Braun, A., Kress, A., Nicolas, A. M., Mohs, K., Becker, C., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.09.014 · Cited by 151
Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor
Bai, X., Yi, M., Jiao, Y., Chu, Q., & Wu, K. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s224013 · Cited by 153
Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy
Achard, C., Surendran, A., Wedge, M.-È., Ungerechts, G., Bell, J. C., & Ilkow, C. S. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.04.020 · Cited by 175
Shaping Up the Tumor Microenvironment With Cellular Fibronectin
Efthymiou, G., Saint, A., Ruff, M., Rekad, Z., Ciais, D., & Obberghen‐Schilling, E. V. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00641 · Cited by 164
“Analysis of histological sections of tumor samples led to the segregation of cancer immune phenotypes into three distinct profiles: immune-inflamed, immune-dessert and immune-excluded (206).”
BackgroundKEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance
Zavitsanou, A., Pillai, R., Yuan, H., Wu, W., Bartnicki, E., Karakousi, T. R., Rajalingam, S., Herrera, A. M., Karatza, A., Rashidfarrokhi, A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113295 · Cited by 177
“T cell infiltration in the tumor microenvironment has been correlated with better prognosis and responses to checkpoint blockade (9,77).”
BackgroundInfluentialImmunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies
To, K. K. W., Fong, W., & Cho, W. C. S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.635007 · Cited by 175
“Using Chen’s classification, tumors with the immune-desert and immune-excluded phenotypes are resistant to PD-1/PD-L1 inhibitors (71).”
BackgroundGenomics and emerging biomarkers for immunotherapy of colorectal cancer
Kather, J. N., Halama, N., & Jaeger, D. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.02.010 · Cited by 150
“(11, 12) MMRd/MSI tumors harbor much more mutations than MMRp/MSS”
BackgroundThe Role of Mitochondrial Dynamics and Mitophagy in Carcinogenesis, Metastasis and Therapy
Wang, Y., Liu, H., Cao, Y., Zhang, L., Huang, F., & Yi, C. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00413 · Cited by 157
Organic Sonodynamic Materials for Combination Cancer Immunotherapy
Zhang, C., & Pu, K. (2023) · Advanced Materials · doi:10.1002/adma.202303059 · Cited by 164
Rational combinations of immunotherapy with radiotherapy in ovarian cancer
Herrera, F. G., Irving, M. B., Kandalaft, L. E., & Coukos, G. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30401-2 · Cited by 162
Damotte, D., Warren, S., Arrondeau, J., Boudou-Rouquette, P., Mansuet-Lupo, A., Biton, J., Ouakrim, H., Alifano, M., Gervais, C., Bellesoeur, A., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2100-3 · Cited by 148
MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma
Hectors, S. J. C. G., Lewis, S. C., Besa, C., King, M. J., Said, D., Putra, J., Ward, S. C., Higashi, T., Thung, S. N., Shen, Y., et al. (2020) · European Radiology · doi:10.1007/s00330-020-06675-2 · Cited by 159
Li, Y., Gu, J., Xu, F., Zhu, Q., Chen, Y., Ge, D., & Lu, C. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa225 · Cited by 168
ICAM-1-mediated adhesion is a prerequisite for exosome-induced T cell suppression
Zhang, W., Zhong, W., Wang, B., Yang, J., Yang, J., Yu, Z., Qin, Z., Shi, A., Xu, W., Zheng, C., et al. (2022) · Developmental Cell · doi:10.1016/j.devcel.2022.01.002 · Cited by 146
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
Morrison, C., Pabla, S., Conroy, J. M., Nesline, M. K., Glenn, S. T., Dressman, D., Papanicolau-Sengos, A., Burgher, B., Andreas, J., Giamo, V., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0344-8 · Cited by 147
“First, these biomarkers inform on key but limited components of the immune cycle [22].”
BackgroundAggarwal, C., Cohen, R. B., Morrow, M. P., Kraynyak, K. A., Sylvester, A. J., Knoblock, D. M., Bauml, J. M., Weinstein, G. S., Lin, A., Boyer, J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1763 · Cited by 146
“Combination strategies may increase the percentage of patients who respond to PD-1 immunotherapy (15, 16).”
BackgroundCD47/SIRPα axis: bridging innate and adaptive immunity
van Duijn, A. V. D. P. , van der Burg, S. H., & Scheeren, F. A. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004589 · Cited by 166
Clinical landscape of macrophage-reprogramming cancer immunotherapies
Rannikko, J. H., & Hollmén, M. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02715-6 · Cited by 184
“A high abundance of immunosuppressive TAMs is characteristic of so-called non-in fl amed tumours that lack T cells and are often resistant to immune checkpoint inhibitor (ICI) therapy, further contributing to poorer prognosis [39].”
Baxevanis, C. N., Fortis, S. P., & Perez, S. A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.018 · Cited by 172
Romero, J. M., Grünwald, B., Jang, G.-H., Bavi, P. P., Jhaveri, A., Masoomian, M., Fischer, S. E., Zhang, A., Denroche, R. E., Lungu, I. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2803 · Cited by 146
Extracellular nucleosides and nucleotides as immunomodulators
Kepp, O., Loos, F., Liu, P., & Kroemer, G. (2017) · Immunological Reviews · doi:10.1111/imr.12571 · Cited by 144
Cancer Immunoediting in the Era of Immuno-oncology
Gubin, M. M., & Vesely, M. D. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1804 · Cited by 184
Challenges in neoantigen-directed therapeutics
Lybaert, L., Lefever, S., Fant, B., Smits, E., De Geest, B., Breckpot, K., Dirix, L., Feldman, S. A., van Criekinge, W., Thielemans, K., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2022.10.013 · Cited by 142
Prospects for combining immune checkpoint blockade with PARP inhibition
Li, A., Yi, M., Qin, S., Chu, Q., Luo, S., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0784-8 · Cited by 143
“An effective anti-cancer immune response relies on the robust cascade reaction including release and presentation of cancer antigens, priming and activation of T cells, trafficking and infiltration of T cells, and recognizing and killing tumor cells [8].”
BackgroundDammeijer, F., Lievense, L. A., Kaijen-Lambers, M. E., van Nimwegen, M., Bezemer, K., Hegmans, J. P., van Hall, T., Hendriks, R. W., & Aerts, J. G. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0309 · Cited by 142
Tunali, I., Gray, J. E., Qi, J., Abdalah, M., Jeong, D. K., Guvenis, A., Gillies, R. J., & Schabath, M. B. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.01.010 · Cited by 144
“However, overall response rates are only about 20 to 50% and those that do not respond can experience accelerated and lethal progression described as hyperprogressive disease (HPD) [7, 8].”
BackgroundPhase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer
Gray, J. E., Saltos, A., Tanvetyanon, T., Haura, E. B., Creelan, B., Antonia, S. J., Shafique, M., Zheng, H., Dai, W., Saller, J. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1305 · Cited by 141
“To this end, immuneexcluded tumors may represent a major subset with primary resistance to ICI in which T cells are trapped in stroma and excluded from tumor beds (6, 35, 36).”
BackgroundSelf-citationKobayashi, H., Furusawa, A., Rosenberg, A., & Choyke, P. L. (2020) · International Immunology · doi:10.1093/intimm/dxaa037 · Cited by 156
Growth and Immune Evasion of Lymph Node Metastasis
Jones, D., Pereira, E. R., & Padera, T. P. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00036 · Cited by 140
“Given the paucity of antitumor T cells and functional lymphatic vessels within some tumors (9, 10), the degree of CD8 T cell interaction with tumor-associated lymphatic vessels and their degree of inhibiting antitumor immunity is unclear.”
BackgroundLimagne, E., Thibaudin, M., Nuttin, L., Spill, A., Derangère, V., Fumet, J.-D., Amellal, N., Peranzoni, E., Cattan, V., & Ghiringhelli, F. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0228 · Cited by 142
Gupta, R. G., Li, F., Roszik, J., & Lizee, G. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1575 · Cited by 152
“tumors with defective T-cell priming, immunological tolerance, or lack of immunogenic antigens) (106).”
BackgroundCell Therapy With TILs: Training and Taming T Cells to Fight Cancer
Kumar, A., Watkins, R., & Vilgelm, A. E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.690499 · Cited by 160
“Tumors that are induced by external carcinogen exposure, such as UV radiation in melanoma and smoking in lung cancer, tend to have high mutational burdens (122) and, therefore, are predicted to be more immunogenic as there are more potential targets for T cells to respond to (123).”
BackgroundTobin, J. W. D., Keane, C., Gunawardana, J., Mollee, P. N., Birch, S. E., Hoang, T., Lee, J. N., Li, L., Huang, L., Murigneux, V., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02365 · Cited by 149
Zhang, M., Liu, Z. Z., Aoshima, K., Cai, W. L., Sun, H., Xu, T., Zhang, Y., An, Y., Chen, J. F.-Y., Chan, L.-H., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abf5473 · Cited by 155
Zhang, Y., Chen, H., Mo, H., Zhao, N., Sun, X., Liu, B., Gao, R., Xu, B., Zhang, Z., Liu, Z., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.01.007 · Cited by 165
The emergence of drug resistance to targeted cancer therapies: Clinical evidence
Sarmento‐Ribeiro, A. B., Scorilas, A., Gonçalves, A. C., Efferth, T., & Trougakos, I. P. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100646 · Cited by 149
Radiation therapy-induced remodeling of the tumor immune microenvironment
Charpentier, M., Spada, S., Nest, S. J. V., & Demaria, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.04.003 · Cited by 159
Thumkeo, D., Punyawatthananukool, S., Prasongtanakij, S., Matsuura, R., Arima, K., Nie, H., Yamamoto, R., Aoyama, N., Hamaguchi, H., Sugahara, S., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110914 · Cited by 152
Obesity and gastrointestinal cancer: the interrelationship of adipose and tumour microenvironments
O'Sullivan, J. N., Lysaght, J., Donohoe, C. L., & Reynolds, J. V. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0069-7 · Cited by 157
Oncolytic Viruses: Priming Time for Cancer Immunotherapy
Russell, L., Peng, K. W., Russell, S. J., & Díaz, R. M. (2019) · BioDrugs · doi:10.1007/s40259-019-00367-0 · Cited by 158
Artificial intelligence in pancreatic cancer
Huang, B., Huang, H., Zhang, S., Zhang, D., Shi, Q., Liu, J., & Guo, J. (2022) · Theranostics · doi:10.7150/thno.77949 · Cited by 142
“Tumor-infiltrating lymphocytes (TILs) have been proven to be associated with immunotherapy response [245], OS, and PFS [246].”
BackgroundFoucher, E. D., Ghigo, C., Chouaib, S., Galon, J., Iovanna, J., & Olive, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01044 · Cited by 138
Interpretable systems biomarkers predict response to immune-checkpoint inhibitors
Lapuente-Santana, Ó., van Genderen, M., Hilbers, P. A. J., Finotello, F., & Eduati, F. (2021) · Patterns · doi:10.1016/j.patter.2021.100293 · Cited by 136
“The positive biomarkers described above are pathways generally associated with inflamed tumors, which are usually more predisposed to responding to ICB immunotherapy.(42) In contrast, for VEGF, we observed a negative association with immune response for 17 cancer types, and no association for ovarian cancer (OV) (Figu…”
BackgroundResultInfluential
Metadata
- Authors
- Chen, D. S., & Mellman, I.
- Affiliations
- Genentech (US)
- Corresponding author
- Mellman, Ira
- Venue
- Nature
- Published
- 2017-01
- Volume
- 541
- Issue
- 7637
- Pages
- 321-330
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2578528809
- Cited by
- 5,352
- References
- 121
- Citations by year
- 2026: 524 · 2025: 527 · 2024: 626 · 2023: 708 · 2022: 848 · 2021: 681 · 2020: 582 · 2019: 386 · 2018: 335 · 2017: 131
- FWCI
- 41.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- antitumor immunity, cancer-immunity cycle, immunotherapy response, CTLA-4, PD-1/PD-L1, immune checkpoint inhibitors, tumor immune microenvironment, immunological profile, predictive biomarkers, durable response
- MeSH terms
- Animals, Humans, Immunologic Memory, Immunotherapy, Inflammation, Neoplasms, T-Lymphocytes, Genome, Human, Tumor Escape, Epigenesis, Genetic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.